Literature DB >> 27540428

Factors Associated with (18)F-Fluorodeoxyglucose Uptake in T1 and T2 Invasive Ductal Carcinoma of the Breast.

So Jung Kim1, Seong-Jang Kim2, In Joo Kim1, Kyoungjune Pak1, Bum Soo Kim1, Seunghyeon Shin1.   

Abstract

PURPOSE: The objective of this study was to investigate the relationship between diversity of (18)F-fluorodeoxyglucose ((18)F-FDG) uptake of primary tumor in positron emission tomography (PET) and various clinicopathologic factors in breast cancer of same pathologic T1, T2 stage.
METHODS: A total of 258 patients with invasive ductal breast cancer were enrolled in this study. All patients underwent (18)F-FDG PET-CT before surgery. Patients were divided into two groups according to tumor size based on the pathologic T stage, and maximum standardized uptake value (SUVmax) of 2.5, respectively.
RESULTS: On the univariate analysis, estrogen receptor (ER), tumor size, lymphovascular invasion, p53, pathologic N status (pN) and Nottingham tumor grade (NG) were associated with high SUVmax in T1 and T2 breast cancer. On the multivariate logistic regression, tumor size and NG remained significant variables dividing high and low SUVmax. In the T1 group, ER, p53 and NG were significantly associated with high SUVmax on the univariate analysis. In this group, p53 and NG remained significant variables for dividing high and low SUVmax on the multivariate logistic regression. In the T2 group, only NG was associated with high SUVmax on the univariate analysis.
CONCLUSIONS: NG showed an association with (18)F-FDG uptake in both T1 and T2 breast cancer independently; however, p53 in T1 breast cancer.

Entities:  

Keywords:  Breast neoplasms; F-18 Fluorodeoxyglucose; Positron emission tomography; TNM staging

Year:  2016        PMID: 27540428      PMCID: PMC4977255          DOI: 10.1007/s13139-016-0409-x

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  29 in total

1.  Breast imaging with fluorine-18-FDG PET: quantitative image analysis.

Authors:  N Avril; S Bense; S I Ziegler; J Dose; W Weber; C Laubenbacher; W Römer; F Jänicke; M Schwaiger
Journal:  J Nucl Med       Date:  1997-08       Impact factor: 10.057

2.  Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems.

Authors:  C Genestie; B Zafrani; B Asselain; A Fourquet; S Rozan; P Validire; A Vincent-Salomon; X Sastre-Garau
Journal:  Anticancer Res       Date:  1998 Jan-Feb       Impact factor: 2.480

3.  Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.

Authors:  N Avril; M Menzel; J Dose; M Schelling; W Weber; F Jänicke; W Nathrath; M Schwaiger
Journal:  J Nucl Med       Date:  2001-01       Impact factor: 10.057

4.  18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.

Authors:  Joseph R Osborne; Elisa Port; Mithat Gonen; Ashley Doane; Henry Yeung; William Gerald; Josh B Cook; Steven Larson
Journal:  J Nucl Med       Date:  2010-03-17       Impact factor: 10.057

5.  Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.

Authors:  R L Wahl; R L Cody; G D Hutchins; E E Mudgett
Journal:  Radiology       Date:  1991-06       Impact factor: 11.105

6.  Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations.

Authors:  N Avril; C A Rosé; M Schelling; J Dose; W Kuhn; S Bense; W Weber; S Ziegler; H Graeff; M Schwaiger
Journal:  J Clin Oncol       Date:  2000-10-15       Impact factor: 44.544

7.  Increased FDG uptake in breast cancer is associated with prognostic factors.

Authors:  Yasemin Sanli; Serkan Kuyumcu; Zeynep Gozde Ozkan; Göknur Işik; Hasan Karanlik; Burcu Guzelbey; Cuneyt Turkmen; Sevda Ozel; Ekrem Yavuz; Ayse Mudun
Journal:  Ann Nucl Med       Date:  2012-02-24       Impact factor: 2.668

8.  Utility of PET in Breast Cancer.

Authors:  Norbert Avril; Marcus Schelling; Jorg Dose; Wolfgang A. Weber; Markus Schwaiger
Journal:  Clin Positron Imaging       Date:  1999-10

Review 9.  Basal breast cancer: a complex and deadly molecular subtype.

Authors:  F Bertucci; P Finetti; D Birnbaum
Journal:  Curr Mol Med       Date:  2012-01       Impact factor: 2.222

10.  Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients.

Authors:  J Alsner; M Yilmaz; P Guldberg; L L Hansen; J Overgaard
Journal:  Clin Cancer Res       Date:  2000-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.